Pallas Capital Advisors LLC Cuts Stake in United Therapeutics Co. (NASDAQ:UTHR)

Pallas Capital Advisors LLC lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,792 shares of the biotechnology company’s stock after selling 103 shares during the quarter. Pallas Capital Advisors LLC’s holdings in United Therapeutics were worth $632,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in shares of United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after buying an additional 45,566 shares during the period. FMR LLC grew its position in United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after purchasing an additional 22,683 shares during the period. Pacer Advisors Inc. increased its stake in United Therapeutics by 0.9% in the 3rd quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock worth $203,078,000 after purchasing an additional 4,869 shares during the period. Finally, Janus Henderson Group PLC lifted its position in United Therapeutics by 12.3% in the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after purchasing an additional 50,409 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Up 0.5 %

UTHR opened at $364.70 on Wednesday. The stock has a market cap of $16.28 billion, a PE ratio of 16.02, a PEG ratio of 1.05 and a beta of 0.57. The business has a 50 day moving average of $370.22 and a 200-day moving average of $352.98. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.38 EPS. Equities analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on UTHR shares. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 8th. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group raised their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Finally, HC Wainwright upped their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $378.36.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $939,625.74. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 7,782 shares of the company’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the transaction, the chief financial officer now owns 6,426 shares in the company, valued at approximately $2,358,277.74. The trade was a 54.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 144,630 shares of company stock valued at $54,371,916 in the last three months. Company insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.